Potassium Chloride

證據等級: L5

預測適應症: 1 個

Potassium Chloride: From Electrolyte Replacement (Hypokalemia) to Renal Tubular Acidosis

One-Sentence Summary

Potassium chloride is a basic electrolyte replacement agent, clinically used to correct hypokalemia; no formal original-indication text is available in this evidence pack. The TxGNN model predicts high relevance to Renal Tubular Acidosis (RTA), a condition in which impaired tubular acid handling frequently causes potassium wasting, with 9 clinical trials and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (`original_indications` empty, no NZ license text available) — potassium chloride's established clinical role is electrolyte (potassium) repletion
Predicted New Indication	Renal Tubular Acidosis
TxGNN Prediction Score	99.87%
Evidence Level	L3 (review articles, observational studies, and mechanistic literature; no completed RCT identified)
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, potassium chloride is an electrolyte-replacement agent used to correct potassium deficiency, and mechanistically may be applicable to renal tubular acidosis by directly replenishing potassium lost through impaired tubular handling.

Renal tubular acidosis (particularly distal/type 1 and type 2 RTA) is characterized by a defect in renal acid-base handling that commonly produces hypokalemia alongside hyperchloremic, normal-anion-gap metabolic acidosis. Correcting the associated electrolyte deficit with potassium salts (potassium chloride, potassium citrate, or potassium bicarbonate) is already an established component of RTA management in the nephrology literature, which is consistent with the TxGNN model's high prediction score.

The mechanistic link here is not a novel pharmacological action but a direct treatment of the electrolyte disturbance that defines the disease — the literature evidence (e.g., Sebastian et al. 1976, on potassium bicarbonate correction in classic RTA) supports plausibility, though most sources describe RTA pathophysiology and diagnosis rather than dedicated potassium chloride efficacy trials.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01834768	Phase 2	Unknown	31	Safety of eplerenone (mineralocorticoid receptor antagonist) in cyclosporine A-treated transplant recipients, relevant to tubular toxicity and electrolyte handling
NCT06867471	N/A	Recruiting	43	Crossover study of exogenous ketosis on proteinuria/renal function in chronic and polycystic kidney disease
NCT01843309	Phase 4	Terminated	36	Spironolactone for prevention of electrolyte abnormalities in amphotericin B-treated patients
NCT07273838	Phase 2	Recruiting	130	SGLT2 inhibitor for acute cardiorenal syndrome/AKI in heart failure patients
NCT01894594	Phase 1	Terminated	7	Alkali therapy (sodium bicarbonate) effect on bicarbonate and potassium levels in Sickle Cell Disease
NCT03354507	N/A	Unknown	40	Sodium bicarbonate for renal tubular acidosis in pediatric epilepsy patients on topiramate
NCT00120731	N/A	Withdrawn	0	Potassium citrate for urinary chemistry/acid-base effects in children with hypercalciuria and urolithiasis
NCT03644706	Phase 3	Terminated	3	ADV7103 vs placebo in preventing metabolic acidosis in pediatric/adult distal RTA (dRTA)
NCT06750172	N/A	Recruiting	33	24-hour urinary aldosterone consistency in diagnosing primary aldosteronism via oral sodium loading test

Literature Evidence

PMID	Year	Type	Journal	Key Findings
783200	1976	Original study	J Clin Invest	In 10 classic (type 1) RTA patients, oral potassium bicarbonate corrected acidosis; sodium conservation was impaired in some patients under sodium restriction
21314872	2011	Review	Int J Clin Pract	Clinical approach to proximal and distal RTA subtypes in adults, including electrolyte correction strategies
3518609	1986	Review	Annu Rev Med	Clinical spectrum of RTA across proximal, hypokalemic distal, and hyperkalemic distal subtypes
8694660	1996	Review	Arch Intern Med	Pathophysiology and diagnostic approach to RTA using urinary and serum electrolytes
17297212	2007	Review	Acta Med Indones	Approach to hypokalemia, including renal causes such as RTA
33459628	2021	Review	Arch Esp Urol	RTA and kidney stone diagnosis/management, including distal RTA mechanisms
22368897	2011	Observational study	JPMA	Prevalence and risk factors of RTA after kidney transplantation
25377117	2014	Review	Nephron Physiol	Effects of mineralocorticoids on acid-base balance and renal acid excretion
33769949	2021	Review	J Am Soc Nephrol	Reassessment of urine anion gap as an indirect measure of ammonium excretion in metabolic acidosis
38445406	2023	Genetic study	La Tunisie Medicale	Genotype-phenotype correlation of distal RTA, including hypokalemia and nephrocalcinosis features

New Zealand Market Information

Currently not marketed in New Zealand; no authorization records are available (total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

TFDA/package-insert safety data is a Blocking data gap (DG001), so the drug cannot yet pass an initial safety (S1) evaluation; the drug is also not currently marketed in New Zealand, and no completed randomized trial directly evaluates potassium chloride for RTA (evidence is largely review/mechanistic/observational, L3).

To proceed, the following is needed:

TFDA-equivalent package insert warnings/contraindications (DG001)
Mechanism of action confirmation via DrugBank (DG002)
Drug-drug interaction data (current query returned no results)
Formal clinical evidence (ideally an RCT or guideline citation) specifically evaluating potassium chloride/potassium salts as therapy for RTA-associated hypokalemia, rather than inferring solely from disease pathophysiology literature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.